Establishment of GDF15 time-resolved fluorescence immunoassay and its clinical application in colorectal cancer.

Meichun Chen, Hongming Fang, Shang Gao, Tianyu Zheng, Shangbin Kao, Yuan Qin, Xueqin Zhao, Xiumei Zhou, Bao Zhu, Biao Huang
Author Information
  1. Meichun Chen: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
  2. Hongming Fang: Affiliated Xiao Shan Hospital, Hangzhou Normal University, Hangzhou, China.
  3. Shang Gao: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
  4. Tianyu Zheng: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
  5. Shangbin Kao: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
  6. Yuan Qin: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
  7. Xueqin Zhao: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
  8. Xiumei Zhou: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. Electronic address: zhouxiumei824@163.com.
  9. Bao Zhu: Department of Nuclear Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, 214023, China. Electronic address: zhubao_999@126.com.
  10. Biao Huang: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. Electronic address: jswxhb@163.com.

Abstract

OBJECTIVE: This study aimed to develop a highly sensitive time-resolved fluoroimmunoassay for growth differentiation factor 15 (GDF15-TRFIA) and investigate its clinical applicability in colorectal cancer (CRC).
METHODS: Using the principle of double-antibody sandwich immunity, the GDF15-TRFIA was established by solid-phase capture antibody and labeled detection antibody with europium as a tracer, the levels of serum GDF15 were quantified in healthy controls (HCs) and patients, and the value of GDF15 in the diagnosis of CRC was analyzed.
RESULTS: The established method has a wide measurement range and good linearity. The HOOK effect was not observed when GDF15 was less than 2000 ng/mL. The intra-analytical coefficients of variation (CVs) were 3.27 %-4.54 %, and the inter-analytical CVs were 5.84 %-10.41 %, and recoveries were 88.15 %-112.36 %. The correlation between GDF15-TRFIA and ELISA was good (�� = 0.9284). Serum GDF15 levels were significantly higher in CRC patients than in benign colorectal tumor (BCT) patients and HCs (P < 0.0001). ROC analysis showed that simultaneous detection of CEA, CA19-9, and GDF15 significantly improved the diagnostic efficiency of CEA and CA19-9.
CONCLUSION: A highly sensitive GDF15-TRFIA method for serum GDF15 was successfully established. It can be used for preliminary diagnosis of CRC, and expected to be a good auxiliary tool for the future clinical diagnosis of CRC.

Keywords

Word Cloud

Created with Highcharts 10.0.0GDF15CRCGDF15-TRFIAclinicalcolorectalcancerestablishedpatientsdiagnosisgoodhighlysensitivetime-resolveddifferentiationfactor15antibodydetectionlevelsserumHCsvaluemethodCVssignificantlyCEACA19-9fluorescenceimmunoassayOBJECTIVE:studyaimeddevelopfluoroimmunoassaygrowthinvestigateapplicabilityMETHODS:Usingprincipledouble-antibodysandwichimmunitysolid-phasecapturelabeledeuropiumtracerquantifiedhealthycontrolsanalyzedRESULTS:widemeasurementrangelinearityHOOKeffectobservedless2000 ng/mLintra-analyticalcoefficientsvariation327 %-454 %inter-analytical584 %-1041 %recoveries8815 %-11236 %correlationELISA�� = 09284SerumhigherbenigntumorBCTP < 00001ROCanalysisshowedsimultaneousimproveddiagnosticefficiencyCONCLUSION:successfullycanusedpreliminaryexpectedauxiliarytoolfutureEstablishmentapplicationColorectalDiagnosticGrowthHighsensitivityTime-resolved

Similar Articles

Cited By